Dapirolizumab pegol is a monoclonal antibody commercialized by UCB, with a leading Phase III program in Systemic Lupus Erythematosus. According to Globaldata, it is involved in 8 clinical trials, of which 5 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Dapirolizumab pegol’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Dapirolizumab pegol is expected to reach an annual total of $69 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Dapirolizumab pegol Overview
Dapirolizumab pegol (CDP-7657) is under development for the treatment of systemic lupus erythematosus (SLE), relapsing multiple sclerosis, relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS). The drug candidate is administered as intravenous infusion. It is a new biological entity (NBE). It is an engineered Fab fragment and polyethylene glycol conjugate. CDP-7657 is humanized anti-CD40L antibody. The drug candidate is developed based on polymer conjugate technology (PEGylation technology). It was also under development for the treatment of amyotrophic lateral sclerosis.
UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, Germany, Italy, Spain, France, China, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.
The company reported revenues of (Euro) EUR5,517 million for the fiscal year ended December 2022 (FY2022), a decrease of 4.5% over FY2021. In FY2022, the company’s operating margin was 10.6%, compared to an operating margin of 22.2% in FY2021. In FY2022, the company recorded a net margin of 7.6%, compared to a net margin of 18.3% in FY2021.
For a complete picture of Dapirolizumab pegol’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.